CA2277075C - Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them - Google Patents

Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them Download PDF

Info

Publication number: CA2277075C
Authority: CA; Canada
Prior art keywords: compound; acid; active ingredient; pharmaceutical compositions; compounds
Prior art date: 1997-01-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2277075A

Other languages

English (en)

French (fr)

Other versions

CA2277075A1 (en

Inventor

Jacob Bar-Tana

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Syndromex Ltd

Original Assignee

Syndromex Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-07

Filing date

1997-12-25

Publication date

2010-06-22

1997-12-25 Application filed by Syndromex Ltd filed Critical Syndromex Ltd

1998-07-16 Publication of CA2277075A1 publication Critical patent/CA2277075A1/en

2010-06-22 Application granted granted Critical

2010-06-22 Publication of CA2277075C publication Critical patent/CA2277075C/en

2017-12-25 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
150000001735 carboxylic acids Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 49
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 13
208000008589 Obesity Diseases 0.000 claims abstract description 11
235000020824 obesity Nutrition 0.000 claims abstract description 11
238000011282 treatment Methods 0.000 claims abstract description 10
208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 6
239000002253 acid Substances 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 12
238000001727 in vivo Methods 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 5
125000001183 hydrocarbyl group Chemical group 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
LLFXYXPRAJLGTE-UHFFFAOYSA-N 2,2,15,15-tetramethylhexadecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCCCC(C)(C)C(O)=O LLFXYXPRAJLGTE-UHFFFAOYSA-N 0.000 claims description 3
MKZKFKFOTOSWSD-UHFFFAOYSA-N 4,4,13,13-tetramethylhexadecanedioic acid Chemical compound OC(=O)CCC(C)(C)CCCCCCCCC(C)(C)CCC(O)=O MKZKFKFOTOSWSD-UHFFFAOYSA-N 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 3
150000008064 anhydrides Chemical class 0.000 claims description 3
125000001246 bromo group Chemical group Br* 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
150000002431 hydrogen Chemical class 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
OAWLZLONZCDJSJ-UHFFFAOYSA-N 2,2,17,17-tetramethyloctadecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCCCCCC(C)(C)C(O)=O OAWLZLONZCDJSJ-UHFFFAOYSA-N 0.000 claims description 2
HSRNAICGDXHMSH-UHFFFAOYSA-N 4,4,11,11-tetramethyltetradecanedioic acid Chemical compound OC(=O)CCC(C)(C)CCCCCCC(C)(C)CCC(O)=O HSRNAICGDXHMSH-UHFFFAOYSA-N 0.000 claims description 2
150000001767 cationic compounds Chemical class 0.000 claims description 2
150000002892 organic cations Chemical class 0.000 claims description 2
UHVWFURTTQVDEO-UHFFFAOYSA-N 4,4,15,15-tetramethyloctadecanedioic acid Chemical compound OC(=O)CCC(C)(C)CCCCCCCCCCC(C)(C)CCC(O)=O UHVWFURTTQVDEO-UHFFFAOYSA-N 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
238000000338 in vitro Methods 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
208000002705 Glucose Intolerance Diseases 0.000 abstract description 7
201000009104 prediabetes syndrome Diseases 0.000 abstract description 7
230000002411 adverse Effects 0.000 abstract description 3
230000037149 energy metabolism Effects 0.000 abstract description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
239000000243 solution Substances 0.000 description 25
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 15
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
239000003921 oil Substances 0.000 description 13
235000019198 oils Nutrition 0.000 description 13
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
239000000725 suspension Substances 0.000 description 10
238000005160 1H NMR spectroscopy Methods 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
-1 alkali metal salts Chemical class 0.000 description 9
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
229910052786 argon Inorganic materials 0.000 description 8
235000005911 diet Nutrition 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
102000004877 Insulin Human genes 0.000 description 7
108090001061 Insulin Proteins 0.000 description 7
239000003814 drug Substances 0.000 description 7
229940125396 insulin Drugs 0.000 description 7
239000002904 solvent Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
229940079593 drug Drugs 0.000 description 6
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
238000003756 stirring Methods 0.000 description 6
150000003626 triacylglycerols Chemical class 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
230000001603 reducing effect Effects 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
208000001145 Metabolic Syndrome Diseases 0.000 description 4
241000700159 Rattus Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000012043 crude product Substances 0.000 description 4
230000037213 diet Effects 0.000 description 4
230000000378 dietary effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
208000006575 hypertriglyceridemia Diseases 0.000 description 4
229960003512 nicotinic acid Drugs 0.000 description 4
239000011664 nicotinic acid Substances 0.000 description 4
235000001968 nicotinic acid Nutrition 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
229960001866 silicon dioxide Drugs 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
229940123208 Biguanide Drugs 0.000 description 3
101150041968 CDC13 gene Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
150000004283 biguanides Chemical class 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
229940043279 diisopropylamine Drugs 0.000 description 3
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 3
238000004821 distillation Methods 0.000 description 3
HKOLTPVNONNDDR-UHFFFAOYSA-N ethyl 4,4-dimethyl-5-oxopent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C=O HKOLTPVNONNDDR-UHFFFAOYSA-N 0.000 description 3
229940125753 fibrate Drugs 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000000055 hyoplipidemic effect Effects 0.000 description 3
201000008980 hyperinsulinism Diseases 0.000 description 3
230000003914 insulin secretion Effects 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
210000005229 liver cell Anatomy 0.000 description 3
230000007170 pathology Effects 0.000 description 3
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 3
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 3
UEWNEQVNIYYFFF-UHFFFAOYSA-N triphenylphosphanium;dibromide Chemical compound [Br-].[Br-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 UEWNEQVNIYYFFF-UHFFFAOYSA-N 0.000 description 3
ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 2
SDENLXLNLFKRAR-UHFFFAOYSA-N 1,14-dibromotetradecane Chemical compound BrCCCCCCCCCCCCCCBr SDENLXLNLFKRAR-UHFFFAOYSA-N 0.000 description 2
WAZHJKKFQRONHO-UHFFFAOYSA-N 2,2,13,13-tetramethyltetradecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCC(C)(C)C(O)=O WAZHJKKFQRONHO-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000032928 Dyslipidaemia Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
206010060378 Hyperinsulinaemia Diseases 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
239000000883 anti-obesity agent Substances 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
235000019577 caloric intake Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000002498 deadly effect Effects 0.000 description 2
235000001916 dieting Nutrition 0.000 description 2
230000037228 dieting effect Effects 0.000 description 2
IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
JDDVKLKOJKGXPA-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCC JDDVKLKOJKGXPA-UHFFFAOYSA-N 0.000 description 2
QQHJDPROMQRDLA-UHFFFAOYSA-N hexadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
230000003451 hyperinsulinaemic effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 2
239000013585 weight reducing agent Substances 0.000 description 2
VJVZPTPOYCJFNI-UHFFFAOYSA-M (2-ethoxy-2-oxoethyl)-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC(=O)OCC)C1=CC=CC=C1 VJVZPTPOYCJFNI-UHFFFAOYSA-M 0.000 description 1
GTQHJCOHNAFHRE-UHFFFAOYSA-N 1,10-dibromodecane Chemical compound BrCCCCCCCCCCBr GTQHJCOHNAFHRE-UHFFFAOYSA-N 0.000 description 1
ZJJATABWMGVVRZ-UHFFFAOYSA-N 1,12-dibromododecane Chemical compound BrCCCCCCCCCCCCBr ZJJATABWMGVVRZ-UHFFFAOYSA-N 0.000 description 1
SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 1
DKEGCUDAFWNSSO-UHFFFAOYSA-N 1,8-dibromooctane Chemical compound BrCCCCCCCCBr DKEGCUDAFWNSSO-UHFFFAOYSA-N 0.000 description 1
BXXWFOGWXLJPPA-UHFFFAOYSA-N 2,3-dibromobutane Chemical compound CC(Br)C(C)Br BXXWFOGWXLJPPA-UHFFFAOYSA-N 0.000 description 1
SJSIHSLNLYLNAU-UHFFFAOYSA-N 2-propyloxane-4-carboxylic acid Chemical compound CCCC1CC(C(O)=O)CCO1 SJSIHSLNLYLNAU-UHFFFAOYSA-N 0.000 description 1
JJMOMMLADQPZNY-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanal Chemical compound OCC(C)(C)C=O JJMOMMLADQPZNY-UHFFFAOYSA-N 0.000 description 1
102000030169 Apolipoprotein C-III Human genes 0.000 description 1
108010056301 Apolipoprotein C-III Proteins 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
HBNPYBPXAYORFB-UHFFFAOYSA-N BrCCCCCCCCCCCCCCBr.CC(C(=O)O)(CCCCCCCCCCCCCCC(C(=O)O)(C)C)C Chemical compound BrCCCCCCCCCCCCCCBr.CC(C(=O)O)(CCCCCCCCCCCCCCC(C(=O)O)(C)C)C HBNPYBPXAYORFB-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
201000001431 Hyperuricemia Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
206010054805 Macroangiopathy Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
235000003339 Nyssa sylvatica Nutrition 0.000 description 1
244000018764 Nyssa sylvatica Species 0.000 description 1
206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000003486 adipose tissue brown Anatomy 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
230000001539 anorectic effect Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000002098 anti-diabetogenic effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
229920000080 bile acid sequestrant Polymers 0.000 description 1
229940096699 bile acid sequestrants Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
239000002036 chloroform fraction Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
VTHIKKVKIVQWHV-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridine Chemical compound [O-2].[O-2].[O-2].[Cr+6].C1=CC=NC=C1 VTHIKKVKIVQWHV-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000010485 coping Effects 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
QXYVMGNNVKUOKQ-AATRIKPKSA-N ethyl (e)-5-hydroxy-4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)\C=C\C(C)(C)CO QXYVMGNNVKUOKQ-AATRIKPKSA-N 0.000 description 1
ZEXBDMFTZCHJOT-UHFFFAOYSA-N ethyl 2-bromoacetate 4,4,11,11-tetramethyltetradecanedioic acid Chemical compound BrCC(=O)OCC.CC(CCC(=O)O)(CCCCCCC(CCC(=O)O)(C)C)C ZEXBDMFTZCHJOT-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
230000000910 hyperinsulinemic effect Effects 0.000 description 1
230000001227 hypertriglyceridemic effect Effects 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000006443 lactic acidosis Diseases 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000000034 method Methods 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000030544 mitochondrion distribution Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
230000010627 oxidative phosphorylation Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
201000008312 primary pulmonary hypertension Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
230000036186 satiety Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
XMRSTLBCBDIKFI-UHFFFAOYSA-N tetradeca-1,13-diene Chemical compound C=CCCCCCCCCCCC=C XMRSTLBCBDIKFI-UHFFFAOYSA-N 0.000 description 1
230000035924 thermogenesis Effects 0.000 description 1
230000000476 thermogenic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/602—Dicarboxylic acid esters having at least two carbon-to-carbon double bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2277075A 1997-01-07 1997-12-25 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them Expired - Fee Related CA2277075C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IL11997197A IL119971A (en)	1997-01-07	1997-01-07	Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
IL119971		1997-01-07
PCT/IL1997/000427 WO1998030530A1 (en)	1997-01-07	1997-12-25	Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Publications (2)

Publication Number	Publication Date
CA2277075A1 CA2277075A1 (en)	1998-07-16
CA2277075C true CA2277075C (en)	2010-06-22

Family

ID=11069666

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2277075A Expired - Fee Related CA2277075C (en)	1997-01-07	1997-12-25	Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Country Status (10)

Country	Link
US (3)	US6284903B1 (2)
EP (2)	EP2112134B1 (2)
JP (2)	JP2001507713A (2)
KR (2)	KR100806928B1 (2)
AT (1)	ATE431816T1 (2)
AU (1)	AU742945B2 (2)
CA (1)	CA2277075C (2)
DE (1)	DE69739415D1 (2)
IL (1)	IL119971A (2)
WO (1)	WO1998030530A1 (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6814962B1 (en) *	1994-06-02	2004-11-09	Aventis Pharma S.A.	Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
IL119971A (en) *	1997-01-07	2003-02-12	Yissum Res Dev Co	Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
IL121165A0 (en)	1997-06-26	1997-11-20	Yissum Res Dev Co	Pharmaceutical compositions containing carboxylic acids and derivatives thereof
MXPA01009893A (es)	1999-04-01	2003-07-28	Esperion Therapeutics Inc	Compuestos con eter, composiciones y usos de estos.
AU2002211666A1 (en)	2000-10-11	2002-04-22	Esperion Therapeutics, Inc.	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
MXPA03003024A (es)	2000-10-11	2003-07-14	Esperion Therapeutics Inc	Compuestos de sulfoxido y bis-sulfoxido y composiciones para el control de colesterol y usos relacionados.
US7304093B2 (en)	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
WO2002030860A2 (en)	2000-10-11	2002-04-18	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
IL155215A0 (en)	2000-10-11	2003-11-23	Esperion Therapeutics Inc	Ether compounds and compositions for cholesterol management and related uses
HUE036646T2 (hu)	2003-01-23	2018-07-30	Esperion Therapeutics Inc	Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
JP2007525408A (ja)	2003-12-24	2007-09-06	エスペリオンセラピューティクス，インコーポレイテッド	コレステロール管理および関連使用のためのケトン化合物および組成物
WO2005062718A2 (en) *	2003-12-30	2005-07-14	Syndromex Ltd.	Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
CA2617213C (en)	2005-07-29	2014-01-28	Resverlogix Corp.	Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2008092231A1 (en)	2007-02-01	2008-08-07	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular diseases
IL181577A0 (en) *	2007-02-26	2007-07-04	Jacob Bar Tana	Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
EP2167069B1 (en)	2007-05-23	2011-10-26	Amcol International Corporation	Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
KR101629356B1 (ko)	2008-06-26	2016-06-13	리스버로직스 코퍼레이션	퀴나졸리논 유도체의 제조방법
AU2010204106B2 (en)	2009-01-08	2014-05-08	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular disease
NZ755378A (en)	2009-03-18	2022-07-29	Resverlogix Corp	Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (ko)	2009-04-22	2019-08-06	리스버로직스 코퍼레이션	신규한 소염제
PE20161551A1 (es)	2009-09-03	2017-01-18	Pfizer Vaccines Llc	Vacuna de pcsk9
CA2812109A1 (en)	2010-09-20	2012-03-29	Kareus Therapeutics, Sa	Methods and compositions for treatment of diabetes and dyslipidemia
US20140004142A1 (en)	2011-03-02	2014-01-02	Pfizer Inc.	Pcsk9 vaccine
RU2640115C2 (ru)	2011-11-01	2017-12-26	Ресверлоджикс Корп.	Фармацевтические композиции замещенных хиназолинонов
WO2013084237A1 (en)	2011-12-08	2013-06-13	Syndromex Ltd.	Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en)	2012-12-21	2019-01-17	Zenith Epigenetics Ltd.	Novel heterocyclic compounds as bromodomain inhibitors
WO2015123291A1 (en)	2014-02-11	2015-08-20	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Pcsk9 vaccine and methods of using the same
JO3789B1 (ar)	2015-03-13	2021-01-31	Resverlogix Corp	التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
RU2022102472A (ru)	2015-03-13	2022-03-15	Эсперион Терапеутикс, Инк.	Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107118098B (zh) *	2016-02-25	2020-07-14	中国科学院上海药物研究所	一类脂肪酸类化合物、其制备方法及其用途
EP3463330B1 (en) *	2016-06-02	2022-05-04	Syndromex Ltd.	Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates
US10512624B2 (en)	2016-11-30	2019-12-24	Syndromex Ltd.	Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1
CN112437766A (zh)	2019-06-21	2021-03-02	艾斯柏伦治疗公司	制备贝派地酸及其组合物的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1268082A (en)	1969-08-08	1972-03-22	Orsymonde	Improvements in or relating to bis-(carboxy-alkylene-thio)-decanes
US3773946A (en) *	1969-09-02	1973-11-20	Parke Davis & Co	Triglyceride-lowering compositions and methods
US3930024A (en) *	1969-09-02	1975-12-30	Parke Davis & Co	Pharmaceutical compositions and methods
BE755550A (fr) *	1969-09-02	1971-02-01	Parke Davis & Co	Acides alcanedioiques, leurs sels et leurs esters abaissant la teneur en triglycerides du serum sanguin
FR2288516A2 (fr) *	1974-10-21	1976-05-21	Orsymonde	Nouveaux bis-(carboxyalcoylene-thio)-1,10 decanes et leurs derives
IL64542A0 (en) *	1981-12-15	1982-03-31	Yissum Res Dev Co	Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) *	1984-06-22	1986-01-02	Epis S.A., Zug	Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4634975A (en) *	1984-09-17	1987-01-06	Progressive Dynamics, Inc.	Method and apparatus for producing electromagnetic surveillance fields
JPS61171417A (ja) *	1985-01-23	1986-08-02	Wakunaga Seiyaku Kk	抗糖尿病剤
DE3512536A1 (de) *	1985-04-06	1986-10-16	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3634356A1 (de) *	1986-10-08	1988-04-21	Epis Sa	Arzneimittel enthaltend alpha-halogenierte dicarbonsaeuren
DE4224670A1 (de) *	1992-07-25	1994-01-27	Boehringer Mannheim Gmbh	Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
US5648387A (en) *	1995-03-24	1997-07-15	Warner-Lambert Company	Carboxyalkylethers, formulations, and treatment of vascular diseases
IL119971A (en) *	1997-01-07	2003-02-12	Yissum Res Dev Co	Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JP2003001549A (ja) *	2001-06-26	2003-01-08	Howa Mach Ltd	光電式刃具折れ検知装置

1997
- 1997-01-07 IL IL11997197A patent/IL119971A/xx not_active IP Right Cessation
- 1997-12-25 KR KR1019997006147A patent/KR100806928B1/ko not_active Expired - Fee Related
- 1997-12-25 JP JP53069798A patent/JP2001507713A/ja not_active Withdrawn
- 1997-12-25 AU AU79947/98A patent/AU742945B2/en not_active Ceased
- 1997-12-25 DE DE69739415T patent/DE69739415D1/de not_active Expired - Lifetime
- 1997-12-25 EP EP09160514.7A patent/EP2112134B1/en not_active Expired - Lifetime
- 1997-12-25 CA CA2277075A patent/CA2277075C/en not_active Expired - Fee Related
- 1997-12-25 AT AT97949080T patent/ATE431816T1/de not_active IP Right Cessation
- 1997-12-25 US US09/331,895 patent/US6284903B1/en not_active Expired - Lifetime
- 1997-12-25 EP EP97949080A patent/EP0988274B1/en not_active Expired - Lifetime
- 1997-12-25 KR KR1020077003601A patent/KR100806927B1/ko not_active Expired - Fee Related
- 1997-12-25 WO PCT/IL1997/000427 patent/WO1998030530A1/en not_active Ceased
2001
- 2001-06-18 US US09/881,812 patent/US6800772B2/en not_active Expired - Lifetime
2003
- 2003-10-08 US US10/680,429 patent/US20040132818A1/en not_active Abandoned
2009
- 2009-11-16 JP JP2009260665A patent/JP5479857B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2010077141A (ja)	2010-04-08
JP2001507713A (ja)	2001-06-12
US6800772B2 (en)	2004-10-05
EP0988274B1 (en)	2009-05-20
ATE431816T1 (de)	2009-06-15
US20040132818A1 (en)	2004-07-08
EP2112134A1 (en)	2009-10-28
IL119971A0 (en)	1997-04-15
CA2277075A1 (en)	1998-07-16
IL119971A (en)	2003-02-12
AU7994798A (en)	1998-08-03
AU742945B2 (en)	2002-01-17
US20020049345A1 (en)	2002-04-25
KR100806928B1 (ko)	2008-02-22
KR20000069934A (ko)	2000-11-25
JP5479857B2 (ja)	2014-04-23
KR20070026888A (ko)	2007-03-08
EP0988274A1 (en)	2000-03-29
WO1998030530A1 (en)	1998-07-16
EP2112134B1 (en)	2013-10-30
DE69739415D1 (de)	2009-07-02
US6284903B1 (en)	2001-09-04
KR100806927B1 (ko)	2008-02-22
EP0988274A4 (en)	2000-10-18

Legal Events

Date	Code	Title	Description
2002-12-23	EEER	Examination request
2018-02-07	MKLA	Lapsed	Effective date: 20171227

Publication	Publication Date	Title
CA2277075C (en)	2010-06-22	Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4634795A (en)	1987-01-06	Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4110351A (en)	1978-08-29	Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
KR101708073B1 (ko)	2017-02-17	록소프로펜 유도체 및 그것을 함유하는 의약
IE49902B1 (en)	1986-01-08	4-substituted-3-hydroxy-3-pyrroline-2,5-dione compounds,process for their preparation and pharmaceutical compositions containing the same
JPH0780807B2 (ja)	1995-08-30	アルファー、オメガ―ジカルボン酸、その製法及びこの化合物を含有する脂質低下剤
Watanabe et al.	1980	Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives
AU4085799A (en)	2000-12-05	Novel diphenylethylene compounds
US4000164A (en)	1976-12-28	Hypolipidemic agents
US3754021A (en)	1973-08-21	4-keto-4-(3-chloro-4'-cyclohexyl)phenylbutyric acid and related compounds
AU3436302A (en)	2002-06-06	Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPH0120127B2 (2)	1989-04-14
EP2226329B1 (en)	2013-07-10	Metal-containing platensimycin analogues
MXPA99006358A (en)	2000-05-01	Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPH03163042A (ja)	1991-07-15	カルコン誘導体
JPH0377179B2 (2)	1991-12-09
SU1015622A1 (ru)	1985-11-30	2-Замещенные 3-окси-5-метил-4-тиофенуксусные кислоты,обладающие противовоспалительной и анальгетической активностью и способ их получени
US4187319A (en)	1980-02-05	Substituted benzaldehyde hypolipidemic agents
US4066788A (en)	1978-01-03	Substituted benzaldehyde hypolipidemic agents
JPS6054318B2 (ja)	1985-11-29	アロイル置換フエニル酢酸誘導体類の製造方法
JPS5936614B2 (ja)	1984-09-05	安息香酸誘導体およびそれらの塩の製造方法
JPH03291266A (ja)	1991-12-20	ピロールアルデヒド誘導体